# Wells Fargo & Company: Form 10-Q for the period ended Sep 30, 2025

- Company: [Wells Fargo & Company](/companies/wfc.md) (CIK 72971)
- Form: 10-Q
- Filed: 2025-10-31
- Accepted by EDGAR: Oct 31, 2025, 16:23 ET
- Period: 2025-09-30
- Accession: 0000072971-25-000253
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/72971/000007297125000253/wfc-20250930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/72971/000007297125000253/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2025-07-01 to 2025-09-30 | $21.44bn | us-gaap:RevenuesNetOfInterestExpense |
| Revenue | 9 months, 2025-01-01 to 2025-09-30 | $62.41bn | us-gaap:RevenuesNetOfInterestExpense |
| Income tax | 3 months, 2025-07-01 to 2025-09-30 | $1.30bn | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2025-01-01 to 2025-09-30 | $2.74bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2025-07-01 to 2025-09-30 | $5.59bn | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2025-01-01 to 2025-09-30 | $15.98bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2025-07-01 to 2025-09-30 | $1.66 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2025-01-01 to 2025-09-30 | $4.64 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2025-07-01 to 2025-09-30 | $1.68 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2025-01-01 to 2025-09-30 | $4.69 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2025-07-01 to 2025-09-30 | 3,223,500,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2025-01-01 to 2025-09-30 | 3,270,300,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2025-01-01 to 2025-09-30 | −$23.12bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Dividends paid | 9 months, 2025-01-01 to 2025-09-30 | $4.04bn | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months, 2025-01-01 to 2025-09-30 | $12.52bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Total assets | at 2025-09-30 | $2.06tn | us-gaap:Assets |
| Total liabilities | at 2025-09-30 | $1.88tn | us-gaap:Liabilities |
| Long-term debt | at 2025-09-30 | $177.77bn | us-gaap:LongTermDebt |
| Short-term borrowings | at 2025-09-30 | $230.65bn | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2025-09-30 | $181.15bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 1,565 characters.

#### Unregistered Issuance of Equity Securities

On August 13, 2025, and August 14, 2025, the Company issued an aggregate of 411,536 shares of common stock to plaintiffs’ counsel as payment in connection with the settlement of the *Himstreet v. Scharf et al.* shareholder derivative action previously disclosed in the Company’s Current Report on Form 8-K filed April 30, 2025. The shares were issued in reliance on the exemption from registration under Section 3(a)(10) of the Securities Act of 1933, as amended.

#### Repurchases of Equity Securities

The following table shows Company repurchases of its common stock for each calendar month in the quarter ended September 30, 2025.

| Calendar month | Total number of shares repurchased (1) | Weighted average price paid per share | Approximate dollar value of shares that may yet be repurchased under the authorization (in millions) |
| --- | ---: | ---: | ---: |
| July | 28,000,000 | $81.76 | $38,468 |
| August | 29,726,893 | 79.05 | 36,118 |
| September | 16,832,532 | 80.84 | 34,758 |
| Total | 74,559,425 |  |  |

(1) A portion of the shares repurchased in July 2025 were under an authorization covering up to $30 billion of common stock approved by the Board of Directors (Board) and publicly announced by the Company on July 25, 2023. All remaining shares were repurchased under an authorization covering up to an additional $40 billion of common stock approved by the Board and publicly announced by the Company on April 29, 2025. Unless modified or revoked by the Board, these authorizations do not expire.

## Risk factors

As filed, 179 characters.

Information in response to this item can be found under the “Financial Review – Risk Factors” section in this Report which information is incorporated by reference into this item.

Filed Oct 31, 2025.
Source: SEC EDGAR, the filing index for accession 0000072971-25-000253. Last ingested by Listed: Nov 13, 2026, 00:23 ET. No prices; not investment advice.